Your browser is no longer supported. Please, upgrade your browser.
Settings
OBSV ObsEva SA daily Stock Chart
OBSV [NASD]
ObsEva SA
Index- P/E- EPS (ttm)-1.02 Insider Own- Shs Outstand26.85M Perf Week7.71%
Market Cap241.92M Forward P/E- EPS next Y-1.81 Insider Trans- Shs Float26.85M Perf Month35.90%
Income-30.20M PEG- EPS next Q-0.33 Inst Own71.20% Short Float0.07% Perf Quarter-31.79%
Sales- P/S- EPS this Y-52.00% Inst Trans- Short Ratio0.79 Perf Half Y-
Book/sh1.56 P/B5.79 EPS next Y5.70% ROA- Target Price24.00 Perf Year-
Cash/sh0.95 P/C9.49 EPS next 5Y- ROE- 52W Range6.11 - 14.69 Perf YTD-22.66%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.69% Beta-
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low47.46% ATR0.74
Employees27 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)60.49 Volatility12.22% 9.22%
OptionableNo Debt/Eq0.00 EPS Q/Q-747.40% Profit Margin- Rel Volume0.36 Prev Close9.04
ShortableYes LT Debt/Eq0.00 EarningsMay 18 BMO Payout- Avg Volume22.70K Price9.01
Recom1.50 SMA2024.12% SMA501.36% SMA200-12.12% Volume8,108 Change-0.33%
Feb-21-17Initiated Leerink Partners Outperform $21
Feb-21-17Initiated Jefferies Buy $21
Feb-21-17Initiated Credit Suisse Outperform $27
May-18-17 07:01AM  ObsEva Reports First Quarter 2017 Financial Results and Business Update GlobeNewswire -6.93%
06:31AM  ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 GlobeNewswire
May-16-17 07:01AM  ObsEva SA to Attend BioEquity Europe 2017 in Paris GlobeNewswire
May-11-17 07:02AM  ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017 GlobeNewswire
Apr-25-17 07:01AM  ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids GlobeNewswire
Mar-24-17 12:02PM  ObsEva SA to Attend Needham Annual Healthcare Conference in NYC GlobeNewswire
12:01PM  ObsEva SA to Attend Needham Annual Healthcare Conference in NYC GlobeNewswire
Mar-17-17 07:02AM  ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor GlobeNewswire
07:01AM  ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor GlobeNewswire
Mar-07-17 07:02AM  ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART GlobeNewswire -5.16%
07:01AM  ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART GlobeNewswire
Feb-21-17 06:55AM  Coverage initiated on ObsEva by Leerink Partners, Jefferies and Credit Suisse
Feb-14-17 09:20AM  Biotech IPOs Slow As Trump-Sown Uncertainty Rattles Nerves On Wall Street Forbes
Feb-06-17 12:31PM  Robust Start for Pharmaceutical IPOs In 2017 Investopedia
12:31PM  Robust Start for Pharmaceutical IPOs In 2017 at Investopedia
Feb-03-17 07:01AM  ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC GlobeNewswire +5.70%
07:01AM  ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC GlobeNewswire
Jan-27-17 06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public at bizjournals.com
06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public American City Business Journals
Jan-26-17 01:30PM  Nasdaq Welcomes ObsEva SA (Nasdaq: OBSV) to The Nasdaq Stock Market GlobeNewswire
06:00AM  ObsEva SA (Nasdaq: OBSV) to Ring The Nasdaq Stock Market Opening Bell in Celebration of its IPO GlobeNewswire
Jan-25-17 11:07PM  ObsEva SA Announces Pricing of Initial Public Offering GlobeNewswire
10:58PM  ObsEva SA Announces Pricing of Initial Public Offering GlobeNewswire
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women between the ages of 15 and 49 suffering from reproductive health and pregnancy. The company intends to develop treatments for treating endometriosis, uterine fibroids, and preterm labor. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; OBE001, an oral oxytocin receptor antagonist to improve clinical pregnancy and live birth rates in women undergoing IVF; and OBE022, an oral and selective prostaglandin F2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of pregnancy. The company was founded in 2012 and is headquartered in Geneva, Switzerland.